title: Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women.
abstract: For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole's long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.
authors.affiliation: South West Wales Cancer Institute, Singleton Hospital, Swansea, UK.
authors.forename: Sharath
authors.initials: S
authors.lastname: Gangadhara
authors.forename: Gianfilippo
authors.initials: G
authors.lastname: Bertelli